BRAF and melanoma: The blockade of MAPK signaling using BRAF/MEK inhibitors has been shown to reduce the production of IL-10, IL-6, and VEGF by melanoma cells, and to inhibit their negative effect on DC differentiation, cytokine production and antigen cross-priming, thus restoring their functions and subsequent anti-melanoma immunity [65,119].